Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors
Cancer Medicine · 2023
DOI: 10.1002/cam4.6549 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Daiki Murata und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Background The presence of cachexia negatively impacts the prognosis of patients with cancer. However, the mechanisms behind the development of cachexia and its prognostic impact on immunotherapy efficacy are not fully understood. Materials and Methods We retrospectively screened patients with advanced or recurrent non‐small cell lung cancer (NSCLC) who received PD‐1/PD‐L1 inhibitor monotherapy. Among 183 patients, pre‐treatment plasma samples were available from 100 patients. We defined cancer cachexia as weight loss of at least 5% during the past 6 months or weight loss of at least 2% and BMI
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan.
- Biostatistics Center, Kurume University School of Medicine, Fukuoka, Japan.
- Department of Diagnostic Pathology, Kurume University Hospital, Fukuoka, Japan.
- Cancer Vaccine and Immunotherapy Center and Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Kanagawa, Japan.
ORCID-Profile: Daiki Murata, Koichi Azuma, Akihiko Kawahara
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Murata, D., Azuma, K., Matsuo, N., Murotani, K., Matama, G., Kawahara, A., Sasada, T., Tokito, T., & Hoshino, T. (2023). Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors. Cancer Medicine. https://doi.org/10.1002/cam4.6549
Vancouver
Murata D, Azuma K, Matsuo N, Murotani K, Matama G, Kawahara A, et al. Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors. Cancer Medicine. 2023. doi:10.1002/cam4.6549
BibTeX
@article{Murata2023,
author = {Murata, Daiki and Azuma, Koichi and Matsuo, Norikazu and Murotani, Kenta and Matama, Goushi and Kawahara, Akihiko and Sasada, Tetsuro and Tokito, Takaaki and Hoshino, Tomoaki},
title = {Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6549}
}
EUVIMED